Rocket Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Rocket Pharmaceuticals, Inc. (RCKT) reported Basic Shares Outstanding (Weighted Average) of 112.84 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 112.84M shares, a 1.64% increase year-over-year.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 112.13M shares, a 1.85% increase year-over-year.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 111.79M shares, a 14.60% increase year-over-year.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 111.57M shares, a 18.49% increase year-over-year.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 111.12M shares, a 17.21% increase from fiscal 2024.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 94.81M shares, a 12.85% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 84.01M shares, a 23.27% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 68.15M shares, a 7.77% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 112.84M shares 10-Q · filed 2026-08-10 | 112.49M shares 10-Q · filed 2026-08-10 | 112.26M shares derived: average of 3 quarters · filed 2026-08-10 | 112.09M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | 112.13M shares 10-Q · filed 2026-05-07 | 111.96M shares derived: average of 2 quarters · filed 2026-05-07 | 111.83M shares derived: average of 3 quarters · filed 2026-05-07 | 111.63M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | 111.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 111.68M shares derived: average of 2 quarters · filed 2026-02-26 | 111.46M shares derived: average of 3 quarters · filed 2026-08-10 | 111.12M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 111.57M shares 10-Q · filed 2025-11-06 | 111.30M shares derived: average of 2 quarters · filed 2026-08-10 | 110.90M shares 10-Q · filed 2025-11-06 | 107.56M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | 111.02M shares 10-Q · filed 2026-08-10 | 110.56M shares 10-Q · filed 2026-08-10 | 106.22M shares derived: average of 3 quarters · filed 2026-08-10 | 103.21M shares derived: average of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | 110.09M shares 10-Q · filed 2026-05-07 | 103.82M shares derived: average of 2 quarters · filed 2026-05-07 | 100.60M shares derived: average of 3 quarters · filed 2026-05-07 | 98.89M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 97.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 95.85M shares derived: average of 2 quarters · filed 2026-02-26 | 95.15M shares derived: average of 3 quarters · filed 2026-02-26 | 94.81M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 94.16M shares 10-Q · filed 2025-11-06 | 93.95M shares derived: average of 2 quarters · filed 2025-11-06 | 93.89M shares 10-Q · filed 2025-11-06 | 93.72M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 93.75M shares 10-Q · filed 2025-08-07 | 93.76M shares 10-Q · filed 2025-08-07 | 93.58M shares derived: average of 3 quarters · filed 2025-08-07 | 90.84M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 93.55M shares 10-Q · filed 2025-05-08 | 93.49M shares derived: average of 2 quarters · filed 2025-05-08 | 89.88M shares derived: average of 3 quarters · filed 2025-05-08 | 87.52M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 93.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 88.04M shares derived: average of 2 quarters · filed 2025-02-27 | 85.52M shares derived: average of 3 quarters · filed 2025-02-27 | 84.01M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 82.64M shares 10-Q · filed 2024-11-07 | 81.55M shares derived: average of 2 quarters · filed 2024-11-07 | 80.87M shares 10-Q · filed 2024-11-07 | 79.73M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 80.47M shares 10-Q · filed 2024-08-06 | 79.97M shares 10-Q · filed 2024-08-06 | 78.77M shares derived: average of 3 quarters · filed 2025-02-27 | 75.63M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 79.45M shares 10-Q · filed 2024-05-07 | 77.91M shares derived: average of 2 quarters · filed 2025-02-27 | 74.01M shares derived: average of 3 quarters · filed 2025-02-27 | 71.88M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 76.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 71.30M shares derived: average of 2 quarters · filed 2025-02-27 | 69.36M shares derived: average of 3 quarters · filed 2025-02-27 | 68.15M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 66.22M shares 10-Q · filed 2023-11-07 | 65.85M shares derived: average of 2 quarters · filed 2023-11-07 | 65.41M shares 10-Q · filed 2023-11-07 | 65.16M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 65.48M shares 10-Q · filed 2023-08-09 | 65.00M shares 10-Q · filed 2023-08-09 | 64.81M shares derived: average of 3 quarters · filed 2024-02-27 | 64.57M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 64.51M shares 10-Q · filed 2023-05-05 | 64.48M shares derived: average of 2 quarters · filed 2024-02-27 | 64.26M shares derived: average of 3 quarters · filed 2024-02-27 | 63.96M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 64.46M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 64.14M shares derived: average of 2 quarters · filed 2024-02-27 | 63.78M shares derived: average of 3 quarters · filed 2024-02-27 | 63.24M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 63.83M shares 10-Q · filed 2022-11-04 | 63.44M shares derived: average of 2 quarters · filed 2022-11-04 | 62.83M shares 10-Q · filed 2022-11-04 | 61.19M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 63.06M shares 10-Q · filed 2022-08-09 | 62.32M shares 10-Q · filed 2022-08-09 | 60.31M shares derived: average of 3 quarters · filed 2023-02-28 | 59.03M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 61.57M shares 10-Q · filed 2022-05-06 | 58.93M shares derived: average of 2 quarters · filed 2023-02-28 | 57.68M shares derived: average of 3 quarters · filed 2023-02-28 | 57.05M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | 56.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 55.74M shares derived: average of 2 quarters · filed 2023-02-28 | 55.55M shares derived: average of 3 quarters · filed 2023-02-28 | 55.38M shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 55.19M shares 10-Q · filed 2021-11-05 | 55.17M shares derived: average of 2 quarters · filed 2021-11-05 | 55.08M shares 10-Q · filed 2021-11-05 | |
| 2020-06-30 | 55.16M shares 10-Q · filed 2021-08-09 | 55.02M shares 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | 54.88M shares 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | 49.01M shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |